Press release
Osteoarthritis Pipeline Witnesses Strong Expansion with 100+ Companies Advancing 110+ Innovative Therapies | DelveInsight
Osteoarthritis Pipeline
DelveInsight's latest report, "Osteoarthritis Pipeline Insights 2026" offers a comprehensive evaluation of the rapidly evolving osteoarthritis (OA) therapeutic landscape. The report highlights the involvement of more than 100 pharmaceutical and biotech companies developing over 110 pipeline candidates targeting osteoarthritis. It provides in-depth coverage of both clinical and preclinical drug candidates, along with detailed insights into therapeutic segmentation by product type, development stage, route of administration, and molecular class. Additionally, the study outlines discontinued and inactive programs within the Osteoarthritis pipeline.
Explore the complete Osteoarthritis Pipeline Analysis and emerging therapies here: https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Highlights from the Osteoarthritis Pipeline Report
* On March 2, 2026, Eli Lilly and Company initiated a Phase III clinical trial evaluating the efficacy and safety of Orforglipron administered once daily in patients with obesity or overweight conditions alongside knee osteoarthritis. The study is designed as a multicenter, randomized, double-blind, placebo-controlled trial.
* The osteoarthritis pipeline demonstrates strong momentum, with over 100 active companies collectively advancing 110+ therapeutic candidates aimed at improving Osteoarthritis treatment outcomes.
* Leading companies in the Osteoarthritis pipeline include Biosplice Therapeutics, Cynata Therapeutics, Regeneron Pharmaceuticals, LG Chem, Bioventus, Asahi Kasei Pharma, Ampio Pharmaceuticals, and several other innovators actively contributing to Osteoarthritis drug development.
* Prominent therapies under development include MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren Registered Gel, Gevokizumab, and others, reflecting a diverse and competitive pipeline landscape.
Gain deeper insights into clinical trials and pipeline progress: Osteoarthritis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Osteoarthritis: Disease Overview
Osteoarthritis (OA) is the most prevalent form of arthritis and is often referred to as degenerative joint disease or "wear-and-tear" arthritis. It primarily affects joints such as the knees, hips, and hands. The condition is characterized by gradual cartilage breakdown, leading to structural changes in the underlying bone.
Patients with Osteoarthritis commonly experience joint pain, stiffness, swelling, and reduced mobility. Symptoms typically worsen over time and may lead to functional impairment or disability. In advanced cases, individuals may struggle to perform daily activities, significantly affecting quality of life.
Emerging Osteoarthritis Therapies
The Osteoarthritis pipeline is enriched with innovative therapies targeting inflammation, cartilage degeneration, and pain management.
* Lorecivivint (Biosplice Therapeutics): A small-molecule CLK/DYRK1A inhibitor that modulates Wnt signaling and inflammatory pathways. It is currently in Phase III trials and is being developed as a disease-modifying osteoarthritis drug (DMOAD) with potential to reduce inflammation, slow cartilage degradation, and promote cartilage regeneration.
* EP-104IAR (Eupraxia Pharmaceuticals): A novel intra-articular therapy designed to provide sustained pain relief through localized corticosteroid delivery. The drug utilizes a polymer-based delivery system to release fluticasone propionate gradually within the knee joint, potentially offering long-lasting efficacy with reduced systemic side effects. It is currently in Phase II trials.
* DFV890 (Novartis): An NLRP3 inflammasome inhibitor targeting inflammatory pathways associated with OA. The drug is under Phase II clinical evaluation for multiple inflammatory conditions, including osteoarthritis.
* 4P004 (4P-Pharma): A GLP-1 analog with anti-inflammatory and cartilage-protective properties, positioned as a potential first-in-class disease-modifying therapy. It is currently in Phase II development.
* GNSC-001 (Genascence): A gene therapy approach utilizing an adeno-associated viral vector to deliver IL-1 receptor antagonist (IL-1Ra), aiming to provide long-term suppression of inflammation with a single injection. It is currently in early-stage clinical trials.
Osteoarthritis Pipeline Insights and Analytical Coverage
The report delivers extensive insights into:
* Osteoarthritis Companies actively engaged in Osteoarthritis drug development and their respective therapeutic portfolios
* Classification of pipeline candidates into early, mid, and late stages of development
* Evaluation of both active and discontinued programs
* Drug categorization based on mechanism of action, route of administration, and molecule type
* Analysis of strategic collaborations, licensing deals, and funding activities shaping the Osteoarthritis market
Explore detailed innovations and unmet needs in Osteoarthritis treatment: Osteoarthritis Unmet Needs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Route of Administration and Molecule Segmentation
Pipeline therapies are categorized based on multiple administration routes, including:
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Additionally, therapies are segmented by molecule type, such as:
* Small molecules
* Monoclonal antibodies
* Recombinant fusion proteins
* Peptides
* Polymers
* Gene therapies
This diversified approach reflects the ongoing efforts to develop more targeted and effective treatment options.
Osteoarthritis Competitive Landscape and Future Outlook
The osteoarthritis pipeline continues to expand as pharmaceutical and biotech companies invest in innovative approaches to address unmet medical needs. The focus on disease-modifying therapies, regenerative medicine, and advanced drug delivery systems is expected to transform the Osteoarthritis treatment paradigm in the coming years.
The report also provides insights into market drivers, barriers, and future opportunities, enabling stakeholders to identify strategic growth areas.
Download the full report to explore future perspectives and market dynamics: Osteoarthritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Osteoarthritis Pipeline Report Scope
* Coverage- Global
* Osteoarthritis Companies- Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, LG Chem, ICM Biotech, Cells for Cells SA, GWOXI Stem Cell Applied Technology, UnicoCell Biomed, Magellan Biologicals, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Orient Europharma, ZYUS Life Sciences, Lubris Biopharma, Saol Therapeutics, Ageless Biotech, Synartro AB, Plakous Therapeutics, Ribomic, Meluha Therapeutics and others.
* Osteoarthritis Pipeline Therapies- MK0663, Etoricoxib, Diacerein, Celecoxib, RTX-GRT7039, Naproxcinod, Naproxen, LY3857210, LY3556050, LY3016859, Ibuprofen, Voltaren Registered Gel, Gevokizumab and others.
* Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discover which companies are leading Osteoarthritis innovation: Osteoarthritis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
* Introduction
* Executive Summary
* Osteoarthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoarthritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lorecivivint: Biosplice Therapeutics
* Mid Stage Products (Phase II)
* EP-104IAR: Eupraxia Pharmaceuticals
* Early Stage Products (Phase I)
* GNSC 001: Genascence
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Inactive Products
* Osteoarthritis Key Companies
* Osteoarthritis Key Products
* Osteoarthritis- Unmet Needs
* Osteoarthritis- Market Drivers and Barriers
* Osteoarthritis- Future Perspectives and Conclusion
* Osteoarthritis Analyst Views
* Osteoarthritis Key Companies
* Appendix
About DelveInsight
DelveInsight is a globally recognized healthcare market research and consulting firm specializing in life sciences. The company delivers high-quality, data-driven insights to support strategic decision-making for pharmaceutical and biotech organizations. With deep industry expertise and customized research solutions, DelveInsight enables clients to stay ahead in an increasingly competitive healthcare landscape.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-pipeline-witnesses-strong-expansion-with-100-companies-advancing-110-innovative-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Pipeline Witnesses Strong Expansion with 100+ Companies Advancing 110+ Innovative Therapies | DelveInsight here
News-ID: 4438747 • Views: …
More Releases from ABNewswire
Delicate Software Solutions Launches Integrated Mobile Attendance and WPS Payrol …
Image: https://www.abnewswire.com/upload/2026/05/f3b64242a299bb3561ef0466eda58eda.jpg
DUBAI, UAE - Delicate Software Solutions, a premier provider of enterprise automation tools in the Middle East, today announced the official launch of its next-generation Integrated Mobile App Attendance System. This innovative solution is designed to work in seamless tandem with their comprehensive HR and Payroll Software [https://www.delicatesoft.com/hr-payroll-software.html], specifically engineered to simplify Wages Protection System (WPS) compliance and workforce management for small and medium-sized enterprises across the United Arab…
New Report Highlights How Ready Logistics Infrastructure Reduces Operational Del …
In logistics, speed is no longer a competitive advantage - it's an expectation. Businesses expanding into new markets or scaling operations often face the same bottleneck: infrastructure. Construction, approvals, and setting up of facilities can sometimes get in the way of your best laid plans. The growing pressure on organisations to deliver faster has created a new game-changer in logistics and industrial property - the ready-to-use logistics park.
Immediate operational readiness
Ready-to-use…
How Excedify Quietly Redefined GD&T Training and Took the Market with It
Excedify, a relatively new entrant in the GD&T training market, has rapidly gained industry attention by shifting the focus from theoretical instruction to practical application. By introducing a structured 4-level learning pathway and integrating tools like a GD&T symbol generator and a browser-based 2D drawing environment, the company has addressed long-standing gaps in traditional training
For decades, the market for GD&T (Geometric Dimensioning and Tolerancing [https://www.excedify.com/bundles/gdt-certification-pathway]) training followed a predictable pattern.…
Excedify Partners with Michael A. Anleitner to Launch Advanced FMEA Online Train …
Excedify has partnered with Michael A. Anleitner, author of The Power of Deduction: Failure Modes & Effects Analysis for Design (2nd Edition), to develop a modern FMEA online training course. The program is based on the AIAG-VDA 7-step method and focuses on practical application, replacing outdated RPN-only approaches with structured Action Priority (AP) analysis.
Germany - May 4, 2026 - Excedify has announced a strategic partnership with Michael A. Anleitner, author…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…
